Melatonina

Tumor prevention by 9-cis-retinoic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin

Breast Cancer Res Treat. 2002 Mar;72(1):33-43.
Nowfar S, Teplitzky SR, Melancon K, Kiefer TL, Cheng Q, Dwived PD, Bischoff ED, Moro K, Anderson MB, Dai J, Lai L, Yuan L, Hill SM.
Combination of Mlt and 9cRA could be a potentially useful clinical treatment regimen for breast cancer.
9-cis-retinoic acid (9cRA)

Does the negative correlation found in breast cancer patients between plasma melatonin and insulin-like growth factor-I concentrations imply the existence of an additional mechanism of oncostatic melatonin influence involved in defense?

Med Sci Monit. 2002 Jun;8(6):CR457-61.
Kajdaniuk D, Marek B, Kos-Kudła B, Zwirska-Korczala K, Ostrowska Z, Buntner B, Szymszal J.
A negative correlation between plasma melatonin and IGF-I concentrations in patients with neoplastic disease imply an additional defense mechanism based on the oncostatic influence of melatonin.
Insulin-like growth factor-I (IGF-I)

MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells

Mol Cell Endocrinol. 2002 Jun 28;192(1-2):147-56.
Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM.
Involvement of the MT(1) melatonin receptor in mediation of melatonin effects on growth-suppression and gene-modulation in breast cancer cells.
MT(1) receptor

Pagine

Abbonamento a RSS - Melatonina